July 5, 2023
Patients with chronic scrotal content pain (CSCP) lack effective, noninvasivetreatment options. We aimed to determine the local and systemic safety, tolerability,pharmacokinetics (PK), and efficacy of a long-lasting local anesthetic in patients with CSCP.
January 5, 2023
A Vancouver-based therapeutics company has received regulatory approval to begin the second Phase II trial of its novel long lasting non-opioid pain medication. Sustained Therapeutics is evaluating a sustained release platform technology that could revolutionize how we treat pain and significantly improve the lives of individuals living with chronic pain.
March 30, 2023
A Vancouver-based therapeutics company has begun a second Phase II trial of its novel long lasting non-opioid pain medication, with a specific focus on treating Chronic Scrotal Pain (CSP), a debilitating condition estimated to affect 1% of the male population. Sustained Therapeutics’ first sustained release drug candidate, ST-01, is designed to slowly release over about 28 days from a single injection.
Automated page speed optimizations for fast site performance